Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lucid Diagnostics Inc. (LUCD)

Lucid Diagnostics reports CMS panel backs EsoGuard payment basis, new CPT code

Neutral Impact 3 of 5 other Written later

Lucid Diagnostics said three public meetings in mid-September advanced payment, billing and coding pathways for its EsoGuard and EsoCheck tests. The filing reports no financial results, and the outcomes remain subject to final determinations, public comment periods and effective dates.

Key points

  • A CMS Medicare Advisory Panel meeting on September 15-16 recommended keeping EsoGuard's original gapfill payment basis under PLA code 0114U; CMS expects final determinations in November.
  • The AMA CPT Editorial Panel approved a new Category III CPT code for nonendoscopic esophageal cell collection on September 17-19.
  • Lucid says it will begin submitting Medicare claims this month for tests at its Texas lab, while claims from its California lab await a final revised LCD.

The filing

CompanyLucid Diagnostics Inc. (LUCD)
Form8-K, current report
Filed with the SECSep 22, 2026, 9:06 AM ET
Accession number0001493152-26-043659

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.